EnVivo Pharmaceuticals, Inc. Presents Additional EVP-6124 Phase 2b Clinical Trial Results at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Published: Oct 31, 2012
WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer’s disease. The data were highlighted in an oral presentation at the 5th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, being held in Monte Carlo, Monaco. New data presented today demonstrate a significant relationship (p=0.003) between EVP-6124 plasma concentrations and the probability of experiencing an improvement in cognition, as measured by the Alzheimer's Disease Assessment Scale-Cognitive subscale-13 (ADAS-Cog-13). Positive results from this Phase 2b trial were also presented in July 2012 during the Late Breaking Novel Therapeutics Session at the Alzheimer’s Association International Conference (AAIC).